[go: up one dir, main page]

TN2009000129A1 - Indole compound - Google Patents

Indole compound

Info

Publication number
TN2009000129A1
TN2009000129A1 TNP2009000129A TN2009000129A TN2009000129A1 TN 2009000129 A1 TN2009000129 A1 TN 2009000129A1 TN P2009000129 A TNP2009000129 A TN P2009000129A TN 2009000129 A TN2009000129 A TN 2009000129A TN 2009000129 A1 TN2009000129 A1 TN 2009000129A1
Authority
TN
Tunisia
Prior art keywords
indole compound
present
glucokinase activator
agent
prodrug
Prior art date
Application number
TNP2009000129A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Osamu Ujikawa
Masahiro Itoh
Kazuko Aoki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000129(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2009000129A1 publication Critical patent/TN2009000129A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
TNP2009000129A 2006-10-19 2009-04-08 Indole compound TN2009000129A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19
PCT/JP2007/070772 WO2008050821A1 (fr) 2006-10-19 2007-10-18 Compose indole

Publications (1)

Publication Number Publication Date
TN2009000129A1 true TN2009000129A1 (en) 2010-10-18

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000129A TN2009000129A1 (en) 2006-10-19 2009-04-08 Indole compound

Country Status (26)

Country Link
US (4) US8410087B2 (fr)
EP (2) EP2074119A1 (fr)
JP (1) JP5260507B2 (fr)
KR (1) KR101444486B1 (fr)
CN (1) CN101573357B (fr)
AU (1) AU2007310064B2 (fr)
BR (1) BRPI0717722A2 (fr)
CA (1) CA2666973C (fr)
CL (1) CL2008001017A1 (fr)
CR (1) CR10748A (fr)
EC (1) ECSP099330A (fr)
GE (1) GEP20115241B (fr)
IL (1) IL198154A (fr)
MA (1) MA30890B1 (fr)
ME (1) ME00681B (fr)
MX (1) MX2009003972A (fr)
MY (1) MY158052A (fr)
NO (1) NO20091948L (fr)
NZ (1) NZ576570A (fr)
PE (1) PE20090884A1 (fr)
RU (1) RU2454415C9 (fr)
TN (1) TN2009000129A1 (fr)
TW (1) TWI460176B (fr)
UA (1) UA97257C2 (fr)
WO (1) WO2008050821A1 (fr)
ZA (1) ZA200902585B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134684B1 (fr) * 2007-04-16 2017-08-02 AbbVie Inc. Indole 7-substitué en tant qu'inhibiteurs de mcl-1
WO2008136428A1 (fr) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cinq chaînons à teneur en azote
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CN101784543B (zh) * 2007-08-17 2013-10-16 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚和吲唑化合物
CN101896483B (zh) 2007-12-20 2013-11-20 株式会社Lg生命科学 葡糖激酶激活剂和包含其作为活性成分的药物组合物
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
WO2009097995A1 (fr) * 2008-02-07 2009-08-13 Sanofi-Aventis Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation
CN102056924B (zh) 2008-04-10 2014-05-21 武田药品工业株式会社 稠环化合物及其用途
US8349886B2 (en) * 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8288559B2 (en) * 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
EP2351743A4 (fr) 2008-10-27 2012-05-09 Takeda Pharmaceutical Composé bicyclique
WO2010076884A1 (fr) 2008-12-29 2010-07-08 武田薬品工業株式会社 Nouveau composé cyclique condensé et utilisation de celui-ci
WO2010117085A1 (fr) * 2009-04-09 2010-10-14 Banyu Pharmaceutical Co.,Ltd. Dérivés d'aryl-indole
JP5657578B2 (ja) 2009-06-09 2015-01-21 武田薬品工業株式会社 新規な縮合環化合物およびその用途
JP5732394B2 (ja) 2009-07-28 2015-06-10 武田薬品工業株式会社 錠剤
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8703758B2 (en) 2010-04-27 2014-04-22 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2011158880A1 (fr) 2010-06-16 2011-12-22 武田薬品工業株式会社 Cristal de composé amide
WO2011159781A2 (fr) * 2010-06-17 2011-12-22 Senomyx, Inc. Modulateurs de goût amer
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US20130184272A1 (en) 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
AR084032A1 (es) 2010-11-30 2013-04-17 Takeda Pharmaceutical Compuesto biciclico
UY33913A (es) 2011-02-17 2012-09-28 Takeda Pharmaceutical Método de producción de derivado de dihidrobenzofurano ópticamente activo
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP6050238B2 (ja) * 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
EP2772485A4 (fr) 2011-10-24 2015-06-10 Takeda Pharmaceutical Composé bicyclique
WO2013105676A1 (fr) 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Dérivés de benzimidazole comme antagonistes du récepteur mch
WO2013122029A1 (fr) 2012-02-13 2013-08-22 武田薬品工業株式会社 Composé à noyaux aromatiques
US9382188B2 (en) 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP2814466B1 (fr) 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Comprimé comprenant 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide ou son sel
EP2838891B1 (fr) 2012-02-24 2017-08-02 Takeda Pharmaceutical Company Limited COMPOSÉ À NOYAU AROMATIQUE COMME INHIBITEURS DE GHRéLINE O-ACYL TRANSFéRASE
CA2868713A1 (fr) 2012-03-29 2013-10-03 Takeda Pharmaceutical Company Limited Compose de type cycle aromatique
EP2836482B1 (fr) 2012-04-10 2019-12-25 The Regents of The University of California Compositions et méthodes pour le traitement du cancer
EP2848622A4 (fr) 2012-05-10 2015-11-04 Takeda Pharmaceutical Composé cyclique aromatique
WO2013168759A1 (fr) 2012-05-10 2013-11-14 武田薬品工業株式会社 Composé cyclique aromatique
CN104519874B (zh) 2012-06-05 2018-08-03 武田药品工业株式会社 固体制剂
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
WO2014165816A1 (fr) 2013-04-05 2014-10-09 North Carolina Central University Composés utiles dans le traitement de troubles métaboliques et leur synthèse
JP2016523809A (ja) 2013-07-09 2016-08-12 武田薬品工業株式会社 複素環化合物
WO2015020184A1 (fr) 2013-08-09 2015-02-12 武田薬品工業株式会社 Composé aromatique
ES2835851T3 (es) * 2013-08-22 2021-06-23 Lg Chemical Ltd Compuesto de indol amida como inhibidor de necrosis
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
WO2018181847A1 (fr) 2017-03-31 2018-10-04 武田薬品工業株式会社 Composé aromatique
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
MY205468A (en) 2018-03-23 2024-10-22 Carmot Therapeutics Inc Modulators of g-protein coupled receptors
AR116019A1 (es) 2018-08-27 2021-03-25 Scohia Pharma Inc Derivados de guanidinobenzoilo como inhibidores de enteropeptidasa
EP3856339A1 (fr) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur gip et leurs utilisations
WO2020067557A2 (fr) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur du gip et leurs utilisations
CN109250963B (zh) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 一种复合增韧混凝土及其制备方法
HUE068174T2 (hu) 2020-02-07 2024-12-28 Gasherbrum Bio Inc Heterociklusos GLP-1 agonisták
PE20221727A1 (es) 2020-03-25 2022-11-04 Takeda Pharmaceuticals Co Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos
JP2023519446A (ja) 2020-03-25 2023-05-10 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物のｑｄ投薬及びその使用
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
BR112023023559A2 (pt) 2021-05-13 2024-02-06 Carmot Therapeutics Inc Moduladores de receptores acoplados à proteína g
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4508047A1 (fr) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
AU2023396387A1 (en) 2022-12-15 2025-06-26 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
EP4638440A1 (fr) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Agonistes hétérocycliques du glp-1
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
WO2025015269A1 (fr) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Composés, compositions et procédés
WO2025015268A1 (fr) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulateurs de l'activité du récepteur de la calcitonine et/ou du récepteur de l'amyline
WO2025045208A1 (fr) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Agonistes de glp-1 à base de hétéroaryl-hétérocycloalkyl
WO2025123039A1 (fr) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Procédé de production de dérivés spiro-oxindole et indoxyl de mitragynine
WO2025137307A1 (fr) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2025154020A1 (fr) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur gip améliorés et leurs utilisations
WO2025154021A1 (fr) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur de gip améliorés et leurs utilisations
WO2025171340A1 (fr) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Traitement d'états associés au récepteur de la calcitonine et/ou de l'amyline

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (fr) 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
PT673937E (pt) * 1993-09-10 2004-04-30 Eisai Co Ltd Derivados biciclicos heterociclicos de sulfonamida e de ester sulfonico
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
TR200002447T2 (tr) * 1998-02-25 2000-11-21 Genetics Institute, Inc. Fosfolinaz enzimlerinin inhibitörleri
JP4007743B2 (ja) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
CA2408913A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
PL375149A1 (en) * 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (fr) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. composes indole substitues et leur utilisation comme modulateurs du recepteur 5-ht6
WO2006112549A1 (fr) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Compose heterocyclique fusionne
WO2007037543A1 (fr) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Dérivé de biarylamide
EP1935890B1 (fr) 2005-09-30 2016-03-16 Msd K.K. Dérivé indole substitué en position 2 par un groupe hétéroaryle
EA201000297A1 (ru) 2007-08-14 2010-08-30 Байер Шеринг Фарма Акциенгезельшафт Конденсированные бициклические имидазолы
CA2694058C (fr) 2007-08-14 2016-06-07 Bayer Schering Pharma Aktiengesellschaft Pyrimidines bicycliques condensees
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
EP2212309B1 (fr) 2007-10-18 2013-06-19 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisubstitués

Also Published As

Publication number Publication date
UA97257C2 (en) 2012-01-25
CA2666973C (fr) 2015-03-31
US7718798B2 (en) 2010-05-18
NO20091948L (no) 2009-07-13
US20080096877A1 (en) 2008-04-24
CA2666973A1 (fr) 2008-05-02
MEP11809A (en) 2011-12-20
JP5260507B2 (ja) 2013-08-14
EP2508524A3 (fr) 2012-10-24
JP2010506825A (ja) 2010-03-04
MY158052A (en) 2016-08-30
RU2009118602A (ru) 2010-11-27
CL2008001017A1 (es) 2009-04-24
PE20090884A1 (es) 2009-08-05
US20100144702A1 (en) 2010-06-10
US7777047B2 (en) 2010-08-17
EP2074119A1 (fr) 2009-07-01
ME00681B (fr) 2011-12-20
TWI460176B (zh) 2014-11-11
WO2008050821A1 (fr) 2008-05-02
CN101573357B (zh) 2013-01-23
GEP20115241B (en) 2011-06-10
NZ576570A (en) 2010-11-26
RU2454415C2 (ru) 2012-06-27
ECSP099330A (es) 2009-06-30
US20100137610A1 (en) 2010-06-03
ZA200902585B (en) 2010-09-29
BRPI0717722A2 (pt) 2013-10-29
MX2009003972A (es) 2009-04-27
IL198154A (en) 2014-08-31
EP2508524A2 (fr) 2012-10-10
RU2454415C9 (ru) 2013-02-27
IL198154A0 (en) 2009-12-24
AU2007310064B2 (en) 2013-03-28
US7652133B2 (en) 2010-01-26
CN101573357A (zh) 2009-11-04
MA30890B1 (fr) 2009-11-02
AU2007310064A1 (en) 2008-05-02
TW200825071A (en) 2008-06-16
CR10748A (es) 2009-05-20
KR101444486B1 (ko) 2014-09-24
US20090286975A1 (en) 2009-11-19
KR20090068292A (ko) 2009-06-25
AU2007310064A2 (en) 2009-06-04
US8410087B2 (en) 2013-04-02

Similar Documents

Publication Publication Date Title
TN2009000129A1 (en) Indole compound
JO2681B1 (en) Indole derivatives
MX2010009736A (es) Compuesto heterociclico.
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MY152475A (en) Fused ring compounds and use thereof
MY154798A (en) Fused cyclic compounds
TW200833675A (en) Nicotinamide derivatives
UA96152C2 (en) Dihydropyrazolopyrimidinone derivatives
TW200745067A (en) Novel compounds
GB0812642D0 (en) Compounds
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
SI2114933T1 (sl) Piperidinski gpcr-agonisti
WO2009016462A3 (fr) Bicyclolactames substitués
TW200732341A (en) Chemical compounds
MY148634A (en) Pyridazinone derivatives
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2010003440A (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MX2010003442A (es) Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo.
GEP20156222B (en) Pyrazole compound